Nick Leschly (Credit: Jeff Rumans at Endpoints News JPM20)
Bluebird hits the brakes on LentiGlobin studies, Zynteglo marketing after AML, myelodysplastic syndrome cases spur fresh safety concerns
Bluebird bio $BLUE has run into a fresh set of troubles for its gene therapy LentiGlobin.
The biotech, which has seen its gene therapy work …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
